CTXR (Citius Pharmaceuticals) Insider Ownership: 2.06 % (As of Aug. 24, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CTXR Citius Pharmaceuticals Inc CTXR
22 GF Score
Price $0.60
! 2 Warning Signs
View Full Analysis

What is Citius Pharmaceuticals Insider Ownership?

Citius Pharmaceuticals CTXR +0.58% 22 Insider Ownership is 2.06 % as of Aug. 24, 2026. GuruFocus rates CTXR with a GF Score™ of 22/100. The stock has 2 warning signs investors should review.

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Citius Pharmaceuticals's insider ownership is 2.06%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Citius Pharmaceuticals's Institutional Ownership is 4.16%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Citius Pharmaceuticals's Float Percentage Of Total Shares Outstanding is 98.21%.

Citius Pharmaceuticals Insider Ownership Historical Data

* Premium members only.

The historical data trend for Citius Pharmaceuticals's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Citius Pharmaceuticals Insider Ownership Chart

Citius Pharmaceuticals Historical Data

The historical data trend for Citius Pharmaceuticals can be seen below:

2024-10-31 2025-08-31 2025-09-30 2025-10-31 2025-11-30 2026-01-31 2026-02-28 2026-05-31 2026-06-30 2026-07-31
Insider Ownership 6.82 61.19 3.32 3.06 3.06 2.52 2.52 2.06 2.06 2.06
CTXR
22GF Score
Citius Pharmaceuticals Inc CTXR
Insider Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Citius Pharmaceuticals Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Frequently Asked Questions Learn more about Insider Ownership →
What does a Insider Ownership of 2.06 % mean?
Citius Pharmaceuticals (CTXR) has a Insider Ownership of 2.06 % as of Aug. 24, 2026. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Citius Pharmaceuticals and its competitors.
Is Citius Pharmaceuticals' Insider Ownership too high?
Citius Pharmaceuticals' current Insider Ownership is 2.06 %. Overall, Citius Pharmaceuticals has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Citius Pharmaceuticals' Insider Ownership compare to LEXX and HIND?
Citius Pharmaceuticals' Insider Ownership of 2.06 % can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Insider Ownership for a Biotechnology company?
A good Insider Ownership depends on the Biotechnology industry context. However, Insider Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Insider Ownership mean?
A high Insider Ownership can signal that a stock is expensive relative to its fundamentals. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Citius Pharmaceuticals and its competitors. Citius Pharmaceuticals's current Insider Ownership is 2.06 %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Citius Pharmaceuticals stock overvalued right now?
Citius Pharmaceuticals (CTXR) has a current Insider Ownership of 2.06 %. The current Insider Ownership is 2.06 %. Citius Pharmaceuticals' overall GF Score™ is 22/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Insider Ownership calculated?
Insider Ownership is calculated from a company's financial statements. For Citius Pharmaceuticals (CTXR), the current Insider Ownership is 2.06 % as of Aug. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Citius Pharmaceuticals Business Description

Address 11 Commerce Drive, First Floor, Cranford, NJ, USA, 07016
Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.
22GF Score

Get the complete analysis for CTXR

Insider Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.60
Price